In non-small cell lung cancer (NSCLC), the KRAS-G12D mutation reduces secretion levels of the chemokines, CXCL10/CXCL11, in the tumor immune microenvironment (TIME) by targeting HMGA2 signaling, leading to a reduction in CD8+ tumor infiltrating lymphocytes, and thereby promoting the effects of anti-PD-1/PD-L1 immunotherapy (Liu et al. 2022). Here, KRAS is linked to non-small cell lung carcinoma.